Erenumab News
Erenumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Erenumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
- Evidence level: L5
- Predicted indications (20):
- migraine with brainstem aura (99.9%)
- migraine disorder (99.9%)
- atrophoderma vermiculata (98.4%)
- migraine with or without aura, susceptibility to (98.3%)
- ulerythema ophryogenesis (97.5%)
- amenorrhea (disease) (97.4%)
- antithrombin deficiency type 2 (97.3%)
- factor 5 excess with spontaneous thrombosis (97.1%)
- heparin cofactor 2 deficiency (97.1%)
- thrombophilia (95.9%)
- sciatic neuropathy (93.5%)
- severe nonproliferative diabetic retinopathy (85.7%)
- hemorrhagic disease of newborn (81.0%)
- HER2 positive breast carcinoma (80.1%)
- normal breast-like subtype of breast carcinoma (77.5%)
- progesterone-receptor positive breast cancer (77.5%)
- breast tumor luminal A or B (77.2%)
- progesterone-receptor negative breast cancer (76.5%)
- infectious bovine rhinotracheitis (73.5%)
- malignant catarrh (73.5%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.